Introduction
============

Urothelial carcinoma (UC), also known as transitional cell carcinoma, is the most common histological type of urinary system malignancy, especially in developed countries [@B1]. UC arises from the urothelium of the entire urinary tract, from the renal pelvis and ureter to the urinary bladder and urethra. The renal pelvis and ureter constitute the upper urinary tract (UUT), and the urinary bladder and urethra constitute the lower urinary tract (LUT). In contrast to UC of the bladder (UCB), the ninth most common malignancy [@B2], UC of the upper urinary tract (UC-UUT) is relatively uncommon and accounts for only 5%-10% of all UCs [@B3]. Although all UCs share some identical carcinogens, such as cigarette smoking and occupational exposure to aromatic amines [@B4]-[@B6], some diseases have a closer relationship with UC-UUT. For example, patients with Chinese herb nephropathy, endemic Balkans nephropathy, and analgesic nephropathy are more susceptible to UC-UUT than UCB [@B7]-[@B10]. Notably, UC-UUT is prevalent in Taiwan, especially in the endemic areas of blackfoot disease, which is caused by arsenic-contaminated water [@B11]-[@B13]. In addition, the gene expression profiles of both UC-UUT and UCB are similar [@B14] and their clinical behaviors are alike after balancing the stage and grade [@B15]. These evidences indicate that the carcinogenesis of UCs along the entire urinary tract may have, at least partly, a similar molecular pathway.

Structural proteins are those forming cellular ultrastructures and include fibrous proteins, globular proteins, motor proteins, and some subsets of membrane proteins. They contribute to extracellular matrix and cytoskeleton formation, cellular motility, and cell-cell adhesion [@B16]. Alterations of these proteins are crucial in the development of tumor invasion and metastasis in oncogenesis [@B17]-[@B19]. However, genes associated with structural molecules have not been systemically evaluated in UCs. By data mining a published dataset of UCB transcriptome (GSE31684) from Gene Expression Omnibus, National Center of Biotechnology Information (GEO, NCBI, Bethesda, MD, USA), we identified that *THBS2* was the most significantly upregulated gene among those related to structural molecule activity (GO:0005198). *THBS2* gene encodes thrombospondin-2 (THBS2, also known as TSP2). THBS2 is a disulfide-linked glycoprotein that mediates extracellular matrix assembly, cell-to-matrix interactions, degradation of matrix metalloproteinase (MMP)-2 and MMP-9, and inhibition of angiogenesis [@B20]. The expression of THBS2 and its prognostic value have been investigated in several cancers [@B21]-[@B28]. Nevertheless, to the best of our knowledge, no study has researched the expression of THBS2 in UCs. Hence, we focused on THBS2 as the target for the experiment detailed in the subsequent section.

Materials and Methods
=====================

Data Mining of Transcriptomic Database from GEO to Identify the Most Altered Gene
---------------------------------------------------------------------------------

A transcriptomic dataset (GSE31684), comprising 93 radically resected UCB cases from GEO, NCBI, was selected for research; of these, 78 belonged to muscle-invasive tumors (pT2 to pT4) and 15 to non-muscle-invasive (pTa and pT1); 28 exhibited distant metastasis whereas 49 did not [@B29]. In this data set, GeneChip^®^ Human Genome U133 Plus 2.0 array (Affymetrix, Santa Clara, CA, USA) was used for analysis. After downloading the raw data, Nexus Expression 3 statistical software (BioDiscovery, El Segundo, CA, USA) was used to analyze all probe sets without filtering or preselection. Moreover, under supervision, we inspected the statistical significance of each transcript by comparing the primary tumor invasiveness and the presence or absence of metastatic diseases. We performed functional profiling by using transcriptomes of muscle-infiltrative UCBs (pT2 to pT4) with metastases and those of non-muscle-infiltrative UCBs (pTa and pT1) without metastasis, targeting the transcriptomes associated with structural molecule activity (GO:0005198). Only genes showing significantly differential expression (*P* \< .01) were enrolled.

Study Cohort of Patients and Specimens
--------------------------------------

The study was approved by the Institutional Review Board of Chi-Mei Medical Center (10501005) and E-Da Hospital (EMRP-104-119). Our well-characterized study cohort comprised 635 consecutive patients with surgically resected UCs from 1996 to 2004 and included 295 patients with UCBs and 340 with UTT-UCs. Histopathological classifications other than UC and variants of UC were excluded. The criteria for inclusion and exclusion and treatment protocols were the same as previously described [@B30].

Immunohistochemistry and Assessment
-----------------------------------

Tissue sections were subjected to the routine procedures of deparaffinization, rehydration, and epitope retrieval and were subsequently incubated with an antibody against THBS2 (1:50, Rabbit polyclonal, Novus Biologicals, Littleton, CO, USA) for 1 hour. XXXX tissues with or without incubation of THBS2 antibody were run in parallel as positive and negative control, respectively. We used the H score method to evaluate the expression of THBS2 protein, which combines the intensity and percentage of immunostaining in the tumor cells to create an H score. The equation for assessing the H score is as follows: H score = Σ*P~i~*(*i*+ 1), where *P~i~* represents the percentage of stained tumor cells (0%-100%) and *i* represents the intensity of immunoreactivity (0-3+). This formula yields a score in the range 100-400, where 100 signifies that 100% of the cancer cells are unreactive and 400 signifies that 100% of the cancer cells are strongly immunoreactive (3+).

Statistical Analyses
--------------------

We used SPSS Version 14.0 (SPSS Inc., Chicago, IL, USA) for statistical analysis. The median H score of THBS2 immunoreactivity was applied as the cut-off value to classify our patient cohort into high- and low-expression subgroups for both the UC-UUT and UCB groups, respectively. We applied Pearson\'s chi-squared test to compare the association between THBS2 expression and miscellaneous critical categorical clinical and pathological parameters and Mann-Whitney U test for numerical parameters. Two prognostic indices, disease-specific survival (DSS) and metastasis-free survival (MeFS) intervals, were determined from the day of surgical excision to the day patient death or occurrence of metastatic disease. Patients lost to follow-up were excluded from the latest follow-up date. For univariate survival analyses, Kaplan-Meier survival curves, with comparison by using log-rank test, were utilized. Parameters demonstrating *P*\< .05 in univariate analyses were included in multivariate tests by using Cox proportional hazards regression. For all statistical analyses, we used two-tailed tests of significance, and only *P*\< .05 was judged to be statistically significant.

Results
=======

*THBS2* as the Most Upregulated Gene among Those Belonging to Structural Molecule Activity (GO:0005198)
-------------------------------------------------------------------------------------------------------

The gene expression profiling is presented in **Fig. [1](#F1){ref-type="fig"}**. By analyzing the published transcriptomic database of UCB (GSE31684) from GEO, 15 probes covering 13 genes related to structural molecule activity (GO:0005198) showed highly significant alteration (*P* \< .01), either upregulation or downregulation, associated with a more aggressive disease. When comparing muscle-infiltrative tumors (pT2 to pT4) to non-muscle-infiltrative tumors (pTa and pT1) and the presence to absence of distant metastasis, 11 genes, *i.e.*, *THBS2*, *COL6A2*, *COL3A1*, *MAP1B*, *COL16A1*, *ACTA2*, *EPB41L3*, *TUBB2B*, *COL8A2*, *COL18A1*, and *PDZD2*, were upregulated to statistical significance (**Table [1](#T1){ref-type="table"}**, all *P*\< .01). Among them, *THBS2* was the most significantly upregulated gene with 2.2182-fold log2 ratio by comparison between more advanced primary tumors (pT2-4) and less advanced ones (pTa and pT1).

Clinical and Pathological Characteristics of Both UC-UUT and UCB Groups
-----------------------------------------------------------------------

As shown in **Table [2](#T2){ref-type="table"}**, there was a male predominance (n = 216, 73.2%) in the UCB group, in contrast to the lack of a gender predominance in the UC-UUT group (M/F, 46.5%/53.5%). In both groups, most patients were elderly (mean age \>65 y). Sixty-two of the 340 patients (18.2%) with UC-UUT had multiple tumors; among them, 49 patients had synchronous tumors in both the renal pelvis and ureter. Most patients had muscle-infiltrating tumors (pT2-4, 46.8% and 41.7% for UC-UUT and UCB groups, respectively). Similarly, most tumors were classified as having a high histopathological grade (83.5% and 81% for UC-UUT and UCB groups, respectively). Furthermore, 8.2% (n = 28) and 9.8% (n = 29) of the patients with UC-UUT and UCB, respectively, had lymph node metastasis at diagnosis. Vascular invasion and perineural invasion were identified in 31.1% (n = 106) and 5.6% (n = 19) UC-UUTs as well as in 16.6% (n = 49) and 6.8% (n = 20) UCBs.

Association Between THBS2 Immunoreactivity and Critical Clinical and Pathological Parameters
--------------------------------------------------------------------------------------------

**Table [2](#T2){ref-type="table"}** shows that high THBS2 expression was significantly associated with a more advanced primary tumor status (pT status, **Fig. [2](#F2){ref-type="fig"}**), lymph node metastasis at diagnosis, and vascular invasion in both UC-UUT and UCB groups (all *P*≤ .001). THBS2 overexpression was significantly associated with perineural invasion in UC-UUTs (*P*= .009) as well as a high histological grade and higher mitotic activity in UCBs (both *P*≤ .001).

Survival Analyses for UC-UUT and UCB Groups
-------------------------------------------

The survival analyses are summarized in **Table [3](#T3){ref-type="table"}**and**Table [4](#T4){ref-type="table"}**. In univariate analysis, advanced primary tumor status (pT), nodal metastatic disease, high histopathological grade, and vascular and perineural invasions were significantly associated with shorter DSS and MeFS intervals in both UC-UUT and UCB groups (all *P \<*.05). Multifocal tumors were significantly linked to both worse DSS (*P*= .0042) and MeFS (*P*= .0196), whereas tumor location was negatively associated with DSS (*P*= .0120) only in the UC-UUT group. High mitotic activity (more than 10 mitoses per 10 high power fields) significantly correlated with both shorter DSS (*P*= .0001) and MeFS (*P*= .0002) intervals in the UCB group.In multivariate analysis of the UC-UUT group, multifocal tumors, nodal metastasis, high histological grade, and perineural invasion were predictive of both adverse DSS and MeFS (all *P*\< .05). Higher pT status and vascular invasion were independent prognosticators for only DSS and MeFS, respectively (both *P*\< .05). Multivariate analysis for UCB group indicated that advanced tumor status was an independent prognostic factor for both adverse DSS and MeFS (*P*\< .001 and *P*= .023, respectively). Perineural invasion and high mitotic rate only predicted dismal DSS (*P*= .009 and *P*= .037, respectively), whereas lymph node metastasis only predicted unfavorable MeFS (*P*= .021).

Prognostic Impact of THBS2 Expression on UC-UUTs and UCBs
---------------------------------------------------------

In univariate analysis, high THBS2 expression was significantly associated with poor DSS and MeFS in both the UC-UUT and UCB groups (**Table [3](#T3){ref-type="table"}**and**Table [4](#T4){ref-type="table"}; Fig. [3](#F3){ref-type="fig"}**, all *P*\< 0.0001). In multivariate analysis, THBS2 overexpression was an independent negative prognosticator that predicted unfavorable outcomes in both UC groups (all *P*\< 0.05).

Discussion
==========

Urothelial carcinoma is a cancer with high recurrent rate and the 5-year overall survival is still unsatisfactory for advanced disease in spite of the introduction of adjuvant chemotherapy [@B31]. Therefore, it is mandatory for scientists and physicians to develop more effective therapeutic strategies for high-risk patients.

THBS2 belongs to the thrombospondin (THBS/TSP) family of five calcium-binding matricellular glycoproteins, THBS1-THBS5. They are classified into two subgroups, namely trimeric and pentameric proteins, according to the oligomerization state and domain structure. THBS1 and THBS2 are trimeric proteins, whereas the others are pentameric [@B32]. THBS1 and THBS2 have similar molecular structures and share 85% amino acid conservation and therefore have similar binding domains. Among the THBS/TSP family of proteins, only THBS1 and THBS2 contain the three type I properdin-like repeats, which contribute to the inhibition of angiogenesis [@B32]. THBS2 interacts with various cell-surface receptors, growth factors, cytokines, and proteases to modulate cell-matrix adhesion, motility, chemotaxis, wound healing, angioinhibition, among others [@B33]. It also participates in tumorigenesis, mainly by inhibiting angiogenesis and by negatively regulating MMP-2 and MMP-9 [@B34]. Therefore, THBS2 is usually considered to a tumor-suppressive gene. However, studies investigating THBS2 expression in various tumors have yielded inconsistent results. In a colorectal cancer study, *THBS2* gene expression was negatively correlated with liver metastasis (*P*= .02) and M1 status (*P*= .03) [@B21]; high THBS2 immunoreactivity was not only associated with tumor response to neoadjuvant chemoradiotherapy but also with an independent and good prognostic factor for DSS and MeFS in patients with rectal cancer [@B28]. In one pancreatic cancer cell line study, the invasive property of the transfectants overexpressing *THBS2* transcripts and protein was significantly suppressed (*P*\< .05) [@B22]. *THBS2* gene downregulation was also observed in prostate cancer tissues and cell lines [@B25]. In addition, overexpression of THBS2 also proved to be a favorable prognostic factor for overall survival in patients with gastric cancer [@B26]. By contrast, in Chijiwa, *et al.*, *THBS2* transcriptional levels were significantly higher in lung adenocarcinoma compared with normal pulmonary tissues (*P*\< .0001) and were significantly higher in tumors with more advanced T statuses and stages compared with early cancers (*P*= .0179 for T3/4 to T1/2; *P*= .0136 for stages II/III to I) [@B23]. In the same study, *THBS2* gene upregulation predicted poor overall survival (*P*= .0139) [@B23]. In a recent study by Naumnik, *et al.*, the serum concentration of THBS2 was significantly higher in patients with non-small cell lung cancer compared with healthy controls (*P*= .002); in addition, high serum concentration of THBS2 correlated with shorter survival (*P*= .007) [@B27]. The conflict maybe due to the divergent role of the same molecule in the differing microenvironments of various cancers. The current work is the first investigating the clinical correlation of THBS2 expression in both UCB and UC-UUT. The oncogenic property of THBS2 on UC maybe related to a mechanism other than the antiangiogenic effect.

Conclusion
==========

The present study revealed overexpression of THBS2 played a significant role in tumor progression of UC. Overexpression of THBS2 was not only significantly associated with aggressive clinicopathological parameters but was also an independent poor prognostic biomarker predicting shorter DSS and MeFS in both UC-UUT and UCB. Additional investigations to elucidate the molecular pathway are necessary for developing potential THBS2-targeted therapies for both groups of UCs, similar to how we have previously developed hopeful molecular targets for UCs [@B35]-[@B41].
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![**Analysis of gene expression in urothelial carcinoma of the urinary bladder by using a published transcriptome data set (GSE31684).** Conducting a clustering analysis of genes by focusing on structural molecule activity (GO:0005198) revealed that *THBS2* was one of the most significantly upregulated genes associated with a more advanced pT status and metastatic disease. Tissue specimens from cancers with distinct pT statuses are illustrated at the top of the heat map, and the expression levels of upregulated and downregulated genes are represented as a continuum of brightness of red or green, respectively. Specimens with unaltered mRNA expression are in black.](jcav07p1541g001){#F1}

![**THBS2 immunostain** on representative tissue sections revealed a stepwise increase of THBS2 immunoreactivity from the normal urothelial epithelium **(A)** to noninvasive papillary (pTa) **(B)**, superficially infiltrating (pT1) **(C)**, and muscle invasive (pT2-pT4) urothelial carcinomas **(D)**.](jcav07p1541g002){#F2}

![**Kaplan-Meier plots** demonstrated the extremely significant prognostic value of THBS2 expression for disease-specific survival (DSS) and metastasis-free survival (MeFS) rates in the UC-UUT (**A** and **B** for DSS and MeFS, respectively) and UCB (**C**and**D** for DSS and MeFS, respectively**)** groups (all *P*\< .0001).](jcav07p1541g003){#F3}

###### 

Summary of differentially expressed genes associated with structural molecule activity (GO:0005198) and showed positive associations to cancer invasiveness and metastasis in the transcriptome of urothelial carcinoma of urinary bladder (GSE31684).

  Probe          Comparing T2-4 to Ta-T1   Comparing Meta. to Non-Meta.^\#^   Gene Symbol   Biological Process   Molecular Function                                                                                                                                                                                                                                                                                                                                               
  -------------- ------------------------- ---------------------------------- ------------- -------------------- -------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------
  203083_at      2.2182                    \<0.0001                           0.9344        0.003                *THBS2*              cell adhesion                                                                                                                                                                                                                                                                                                                               calcium ion binding, heparin binding, protein binding, structural molecule activity
  209156_s\_at   2.1304                    \<0.0001                           0.9732        0.0021               *COL6A2*             cell adhesion, cell-cell adhesion, extracellular matrix organization and biogenesis, phosphate transport                                                                                                                                                                                                                                    extracellular matrix structural constituent, protein binding, protein binding; bridging, structural molecule activity
  215076_s\_at   1.4494                    \<0.0001                           0.5177        0.0031               *COL3A1*             circulation, organ morphogenesis, phosphate transport                                                                                                                                                                                                                                                                                       extracellular matrix structural constituent, structural molecule activity
  226084_at      1.2832                    \<0.0001                           0.9436        \<0.0001             *MAP1B*              dendrite development, microtubule bundle formation                                                                                                                                                                                                                                                                                          protein binding, structural molecule activity
  204345_at      1.274                     \<0.0001                           0.5661        0.001                *COL16A1*            cell adhesion, female pregnancy, integrin-mediated signaling pathway, phosphate transport                                                                                                                                                                                                                                                   integrin binding, protein binding, structural molecule activity
  200974_at      1.2155                    0.0002                             0.6759        0.0087               *ACTA2*                                                                                                                                                                                                                                                                                                                                                          ATP binding, nucleotide binding, protein binding, structural molecule activity
  212681_at      1.0972                    0.0001                             1.2658        \<0.0001             *EPB41L3*            cortical actin cytoskeleton organization and biogenesis                                                                                                                                                                                                                                                                                     actin binding, binding, cytoskeletal protein binding, protein binding, structural molecule activity
  214023_x\_at   0.9093                    0.0018                             0.9548        \<0.0001             *TUBB2B*             microtubule-based movement, microtubule-based process, protein polymerization                                                                                                                                                                                                                                                               GTP binding, GTPase activity, nucleotide binding, protein binding, structural constituent of cytoskeleton, structural molecule activity
  221900_at      0.8558                    \<0.0001                           0.3936        0.0014               *COL8A2*             cell adhesion, cell-cell adhesion, extracellular matrix organization and biogenesis, phosphate transport                                                                                                                                                                                                                                    extracellular matrix structural constituent, protein binding, protein binding; bridging, structural molecule activity
  213290_at      0.832                     0.0002                             0.5142        0.004                *COL6A2*             cell adhesion, cell-cell adhesion, extracellular matrix organization and biogenesis, phosphate transport                                                                                                                                                                                                                                    extracellular matrix structural constituent, protein binding, protein binding; bridging, structural molecule activity
  209082_s\_at   0.6536                    0.0015                             0.4516        0.0042               *COL18A1*            angiogenesis, cell adhesion, endothelial cell morphogenesis, extracellular matrix organization and biogenesis, negative regulation of cell proliferation, organ morphogenesis, phosphate transport, positive regulation of apoptosis, positive regulation of cell migration, positive regulation of cell proliferation, visual perception   extracellular matrix structural constituent, metal ion binding, protein binding, structural molecule activity, zinc ion binding
  209493_at      0.4147                    0.0095                             0.436         0.0003               *PDZD2*              cell adhesion                                                                                                                                                                                                                                                                                                                               protein binding, structural molecule activity
  214577_at      0.3773                    0.0029                             0.3943        \<0.0001             *MAP1B*              dendrite development, microtubule bundle formation                                                                                                                                                                                                                                                                                          protein binding, structural molecule activity

\#, Meta., distal metastasis developed during follow-up; Non-Meta.: no metastatic event developed.

###### 

Correlations between THBS2 Expression and other important clinicopathological parameters in urothelial carcinomas.

  Parameter                                     Category         Upper Urinary Tract Urothelial Carcinoma   Urinary Bladder Urothelial Carcinoma                                                                     
  --------------------------------------------- ---------------- ------------------------------------------ -------------------------------------- --------------- ----------- ----- --------------- --------------- -----------
  Gender^&^                                     Male             158                                        75                                     83              0.384       216   110             106             0.534
  Female                                        182              95                                         87                                                     79          37    42                              
  Age (years)^\#^                                                340                                        65.94+/-10.01                          65.22+/-9.69    0.214       295   66.04+/-12.67   66.05+/-11.78   0.704
  Tumor location^&^                             Renal pelvis     141                                        70                                     71              0.685       \-    \-              \-              \-
  Ureter                                        150              78                                         72                                                     \-          \-    \-              \-              
  Renal pelvis & ureter                         49               22                                         27                                                     \-          \-    \-              \-              
  Multifocality^&^                              Single           278                                        142                                    136             0.339       \-    \-              \-              \-
  Multifocal                                    62               28                                         34                                                     \-          \-    \-              \-              
  Primary tumor (pT)^&^                         pTa              89                                         63                                     26              \<0.001\*   84    68              16              \<0.001\*
  pT1                                           92               50                                         42                                                     88          46    42                              
  pT2-pT4                                       159              57                                         102                                                    123         33    90                              
  Nodal metastasis^&^                           Negative (pN0)   312                                        163                                    149             \<0.001\*   266   141             125             0.001\*
  Positive (pN1-pN3)                            28               7                                          21                                                     29          6     23                              
  Histological grade ^&^                        Low grade        56                                         34                                     22              0.079       56    44              12              0.001\*
  High grade                                    284              136                                        148                                                    239         103   136                             
  Vascular invasion^&^                          Absent           234                                        132                                    102             \<0.001\*   246   134             112             \<0.001\*
  Present                                       106              38                                         68                                                     49          13    36                              
  Perineural invasion^&^                        Absent           321                                        166                                    155             0.009\*     275   141             134             0.066
  Present                                       19               4                                          15                                                     20          6     14                              
  Mitotic rate (per 10 high power fields)^\#^                    340                                        11.59+/-12.31                          13.02+/-12.24   0.072       295   12.10+/-14.67   16.70+/-13.03   \<0.001\*

&, Chi-Square test; \#, Mann-Whitney U test; \* Statistically significant.

###### 

Univariate log-rank and multivariate analyses for Disease-specific and Metastasis-free Survivals in upper urinary tract urothelial carcinoma.

  Parameter                                 Category         Case No.   Disease-specific Survival   Metastasis-free Survival                                                                          
  ----------------------------------------- ---------------- ---------- --------------------------- -------------------------- -------------- ----- ----------- ---- ------------ -------------- ---- ---------
  Gender                                    Male             158        28                          0.9301                     \-             \-    \-          32   0.7904       \-             \-   \-
  Female                                    182              33                                     \-                         \-             \-    38               \-           \-             \-   
  Age (years)                               \< 65            138        26                          0.8660                     \-             \-    \-          30   0.8470       \-             \-   \-
  ≥ 65                                      202              35                                     \-                         \-             \-    40               \-           \-             \-   
  Tumor side                                Right            177        34                          0.7188                     \-             \-    \-          38   0.3074       \-             \-   \-
  Left                                      154              26                                     \-                         \-             \-    32               \-           \-             \-   
  Bilateral                                 9                1                                      \-                         \-             \-    0                \-           \-             \-   
  Tumor location                            Renal pelvis     141        24                          0.0120\*                   1              \-    0.976       31   0.0659       \-             \-   \-
  Ureter                                    150              22                                     0.940                      0.500-1.767          25               \-           \-             \-   
  Renal pelvis & ureter                     49               15                                     1.140                      0.319-4.074          14               \-           \-                  
  Multifocality                             Single           273        48                          0.0042\*                   1              *-*   0.012\*     52   0.0196\*     1              \-   0.006\*
  Multifocal                                62               18                                     2.729                      1.247-5.973          18               2.175        1.254-3.773         
  Primary tumor (pT)                        pTa              89         2                           \<0.0001\*                 1              \-    0.040\*     4    \<0.0001\*   1              \-   0.228
  pT1                                       92               9                                      3.086                      0.656-14.514         15               2.712        0.877-8.383         
  pT2-pT4                                   159              50                                     4.580                      1.003-20.919         51               2.479        0.770-7.976         
  Nodal metastasis                          Negative (pN0)   312        42                          \<0.0001\*                 1              \-    \<0.001\*   55   \<0.0001\*   1              \-   0.002\*
  Positive (pN1-pN3)                        28               19                                     4.935                      2.681-9.085          15               2.623        1.578-4.847         
  Histological grade                        Low grade        56         4                           0.0171\*                   1              \-    0.026\*     3    0.0019\*     1              \-   0.126\*
  High grade                                284              57                                     3.099                      1.144-8.395          67               2.862        1.420-11.425        
  Vascular invasion                         Absent           234        24                          \<0.0001\*                 1              \-    0.084       26   \<0.0001\*   1              \-   0.001\*
  Present                                   106              37                                     1.691                      0.932-3.068          44               2.643        1.456-4.130         
  Perineural invasion                       Absent           321        50                          \<0.0001\*                 1              \-    0.001\*     61   \<0.0001\*   1              \-   0.029\*
  Present                                   19               11                                     3.375                      1.608-7.084    \--   9                2.282        1.089-4.784         
  Mitotic rate (per 10 high power fields)   \< 10            173        27                          0.1268                     \-             \-    \-          30   0.0581       \-             \-   \-
  \>= 10                                    167              34                                     \-                         \-             \-    40               \-           \-             \-   
  THBS2 expression                          Low              170        14                          \<0.0001\*                 1              \-    0.017\*     17   \<0.0001\*   1              \-   0.002\*
  High                                      170              47                                     2.133                      1.146-3.969          53               2.471        1.401-4.357         

\* Statistically significant.

###### 

Univariate log-rank and multivariate analyses for Disease-specific and Metastasis-free Survivals in urinary bladder urothelial carcinoma.

  Parameter                                 Category         Case No.   Disease-specific Survival   Metastasis-free Survival                                                                          
  ----------------------------------------- ---------------- ---------- --------------------------- -------------------------- --------------- ---- ----------- ---- ------------ -------------- ---- ---------
  Gender                                    Male             216        41                          0.4906                     \-              \-   \-          61   0.2745       \-             \-   \-
  Female                                    79               11                                     \-                         \-              \-   16               \-           \-             \-   
  Age (years)                               \< 65            121        17                          0.1315                     \-              \-   \-          32   0.8786       \-             \-   \-
  ≥ 65                                      174              35                                     \-                         \-              \-   45                                                
  Primary tumor (pT)                        pTa              84         1                           \<0.0001\*                 1               \-   \<0.001\*   4    \<0.0001\*   1              \-   0.023\*
  pT1                                       88               9                                      4.203                      0.463-38.147         23               3.326        0.998-11.080        
  pT2-pT4                                   123              42                                     18.697                     2.142-163.230        50               5.159        1.528-17.418        
  Nodal metastasis                          Negative (pN0)   266        41                          0.0001\*                   1               \-   0.550       61   \<0.0001\*   1              \-   0.021\*
  Positive (pN1-pN3)                        29               11                                     1.242                      0.610-2.530          16               2.050        1.114-3.773         
  Histological grade                        Low grade        56         2                           0.0016\*                   1               \-   0.854       5    0.0007\*     1              \-   0.924
  High grade                                239              50                                     1.158                      0.243-5.518          72               1.052        0.367-3.015         
  Vascular invasion                         Absent           246        37                          0.0010\*                   1               \-   0.181       54   \<0.0001\*   1              \-   0.665
  Present                                   49               15                                     0.629                      0.319-1.240          23               1.141        0.630-2.063         
  Perineural invasion                       Absent           275        44                          \<0.0001\*                 1               \-   0.009\*     67   0.0003\*     1              \-   0.085
  Present                                   20               8                                      3.004                      1.313-6.874          10               1.886        0.916-3.881         
  Mitotic rate (per 10 high power fields)   \< 10            139        12                          0.0001\*                   1               \-   0.037\*     23   0.0002\*     1              \-   0.086
  \>= 10                                    156              40                                     2.054                      1.044-4.039          54               1.572        0.938-2.635         
  THBS2 expression                          Low              147        10                          \<0.0001\*                 1               \-   0.033\*     18   \<0.0001\*   1              \-   0.004\*
  High                                      148              42                                     2.204                      1.065-4.562          59               2.275        1.307-3.960         

\* Statistically significant.
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